Literature DB >> 17591767

Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.

Emily B Askew1, Robert T Gampe, Thomas B Stanley, Jonathan L Faggart, Elizabeth M Wilson.   

Abstract

The androgen receptor (AR) is transcriptionally activated by high affinity binding of testosterone (T) or its 5alpha-reduced metabolite, dihydrotestosterone (DHT), a more potent androgen required for male reproductive tract development. The molecular basis for the weaker activity of T was investigated by determining T-bound ligand binding domain crystal structures of wild-type AR and a prostate cancer somatic mutant complexed with the AR FXXLF or coactivator LXXLL peptide. Nearly identical interactions of T and DHT in the AR ligand binding pocket correlate with similar rates of dissociation from an AR fragment containing the ligand binding domain. However, T induces weaker AR FXXLF and coactivator LXXLL motif interactions at activation function 2 (AF2). Less effective FXXLF motif binding to AF2 accounts for faster T dissociation from full-length AR. T can nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer mutation. The Tyr-874 mutant side chain mediates a new hydrogen bonding scheme from exterior helix-10 to backbone protein core helix-4 residue Tyr-739 to rescue T-induced AR activity by improving AF2 binding of FXXLF and LXXLL motifs. Greater AR AF2 activity by improved core helix interactions is supported by the effects of melanoma antigen gene protein-11, an AR coregulator that binds the AR FXXLF motif and targets AF2 for activation. We conclude that T is a weaker androgen than DHT because of less favorable T-dependent AR FXXLF and coactivator LXXLL motif interactions at AF2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591767      PMCID: PMC4075031          DOI: 10.1074/jbc.M703268200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer.

Authors:  W Huang; Y Shostak; P Tarr; C Sawyers; M Carey
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.

Authors:  B He; J A Kemppainen; J J Voegel; H Gronemeyer; E M Wilson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

3.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

4.  Contribution of hydrogen bonds to the conformational stability of human lysozyme: calorimetry and X-ray analysis of six Ser --> Ala mutants.

Authors:  K Takano; Y Yamagata; M Kubota; J Funahashi; S Fujii; K Yutani
Journal:  Biochemistry       Date:  1999-05-18       Impact factor: 3.162

5.  Phenotypic diversity and testosterone-induced normalization of mutant L712F androgen receptor function in a kindred with androgen insensitivity.

Authors:  P M Holterhus; G H Sinnecker; O Hiort
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

6.  Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.

Authors:  Q Wang; J Lu; E L Yong
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

7.  Binding of buried structural water increases the flexibility of proteins.

Authors:  S Fischer; C S Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

8.  Hormonal predictors of prostate cancer: a meta-analysis.

Authors:  T Shaneyfelt; R Husein; G Bubley; C S Mantzoros
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

9.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

10.  Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone.

Authors:  J A Kemppainen; E Langley; C I Wong; K Bobseine; W R Kelce; E M Wilson
Journal:  Mol Endocrinol       Date:  1999-03
View more
  69 in total

1.  Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.

Authors:  Yan-Guang Wu; Jill Bennett; Deepika Talla; Carlos Stocco
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

3.  Design and synthesis of a new steroid-macrocyclic derivative with biological activity.

Authors:  Maria López-Ramos; Lauro Figueroa-Valverde; Socorro Herrera-Meza; Marcela Rosas-Nexticapa; Francisco Díaz-Cedillo; Elodia García-Cervera; Eduardo Pool-Gómez; Regina Cahuich-Carrillo
Journal:  J Chem Biol       Date:  2017-02-23

4.  Nitric oxidergic cells related to ejaculation in gerbil forebrain contain androgen receptor and respond to testosterone.

Authors:  Danielle A Simmons; Pauline Yahr
Journal:  J Comp Neurol       Date:  2011-04-01       Impact factor: 3.215

Review 5.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

6.  Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.

Authors:  Adam R Karpf; Suxia Bai; Smitha R James; James L Mohler; Elizabeth M Wilson
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

7.  Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11.

Authors:  Emily B Askew; Suxia Bai; Amanda B Parris; John T Minges; Elizabeth M Wilson
Journal:  Mol Cell Endocrinol       Date:  2016-12-29       Impact factor: 4.102

8.  Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Authors:  Dennis J van de Wijngaart; Michel Molier; Scott J Lusher; Remko Hersmus; Guido Jenster; Jan Trapman; Hendrikus J Dubbink
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

9.  Steroid 5α-reductase in adult rat brain after neonatal dihydrotestosterone administration.

Authors:  P Sánchez; J M Torres; B Castro; R G Del Moral; J de Dios Luna; E Ortega
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

10.  Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.

Authors:  Ravi Jasuja; Jagadish Ulloor; Christopher M Yengo; Karen Choong; Andrei Y Istomin; Dennis R Livesay; Donald J Jacobs; Ronald S Swerdloff; Jaroslava Miksovská; Randy W Larsen; Shalender Bhasin
Journal:  Mol Endocrinol       Date:  2009-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.